Victor Yazbeck, MD
Hematology & Oncology · Richmond, VANPI 1154584662
Payments from drug & device makers
Across 275 payments — averaging $2748.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$138K
- Gilead$106K
- AstraZeneca$91K
- AbbVie$61K
- Beone Medicines USA, Inc.$60K
- F. Hoffmann-la Roche AG$53K
- plus $248K from 15 others
Across 10 payments — averaging $259.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
- F. Hoffmann-la Roche AG$1K
- AbbVie$211
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 73 | $138,091 |
| Gilead(2 entities) | 14 | $105,766 |
| AstraZeneca | 52 | $90,746 |
| AbbVie | 9 | $60,502 |
| Beone Medicines USA, Inc. | 14 | $59,792 |
| F. Hoffmann-la Roche AG | 2 | $52,947 |
| Beigene USA, Inc. | 42 | $49,525 |
| Regeneron | 6 | $45,940 |
| Eli Lilly | 3 | $40,941 |
| Genmab A/s | 11 | $37,385 |
| Pfizer | 5 | $19,333 |
| ADC Therapeutics America, Inc. | 14 | $15,800 |
| Verastem, Inc. | 5 | $10,685 |
| Beigene, Ltd. | 3 | $10,055 |
| Merck | 9 | $7,482 |
| Incyte Corporation | 2 | $4,210 |
| Acrotech Biopharma Inc. | 6 | $3,543 |
| Bristol Myers Squibb | 2 | $1,446 |
| Janssen Scientific Affairs, LLC | 1 | $1,363 |
| Genentech, Inc. | 1 | $177 |
| Kyowa Kirin, Inc. | 1 | $49 |
How this compares
$755,778 in reported general payments places this provider in the 85th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Richmond
- Erin AlesiRichmond$1.7M
- Sarah GordonRichmond$1M
- Will VoelzkeRichmond$774K
- James KhatcheressianRichmond$773K
- William ClarkRichmond$685K
- Elke FriedmanRichmond$571K
- Joshua McFarlaneRichmond$390K
- Jonathan BerkmanRichmond$360K
- Reed MitchellRichmond$357K
- Hashim MannRichmond$331K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.